Aug. 13 at 12:22 PM
$PMN
🚨 🚨 🚨
ProMIS Neurosciences reported a cash balance of
$4,510,119 and total assets of
$9,509,496 at June 30, 2025, with a shareholders' deficit of $(382,578).
The company recorded a net loss of
$10,117,029 for the three months and
$17,464,932 for the six months ended June 30, 2025, producing negative operating cash flow of
$8,781,048 for the six-month period.
Quarterly operating expenses were
$10,184,661, driven by
$8,050,610 of PMN310 development costs this quarter and
$12,776,951 year-to-date.
Accrued liabilities rose to
$7,043,908 from
$480,962 at year-end.
Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing.
